BIO-Europe Spring EBD Group BIO Image Map
Email this page Share this on LinkedIn Share this on Twitter

BIO-Europe Spring® 2015 Press Releases

December 16, 2014Paris, France will host BIO-Europe Spring® 2015 international life science partnering conference The ninth annual BIO-Europe Spring® conference will be held March 9–11, 2015 in Paris, France at the Paris expo Porte de Versailles conference center. This is the first time Paris will host a life science industry event of this scale, and it is expected to draw a large number of established biotech and early stage companies desiring to form business partnerships with invest...  more ►

November 20, 2014Spotlight on Paris Your browser does not support the video tag. Business Facts The Paris region is Europe's No. 1 business region with 842,000 businesses, from high tech sectors to traditional industrial activities. Paris is an innovation hotspot and has eight competitive clusters enhancing innovation, and the most generous research tax credits in Europe. There were 4,800 patents filed in the Paris re...  more ►

partnering360® Blog

May 5, 2015 Help us reach our 30,000 members milestone and you could be a winner! partnering360®, your life science dealmaker network, is about to celebrate a milestone. We are nearing our 30,000th member, and as part of the celebration, we want to offer you a chance to win a FREE ticket to an EBD Group event. Simply encourage your colleagues and associates to join you as member... more ►

May 1, 2015 San Diego-based company defines what it means to be a “disruptor” You hear a lot these days about “disruptive technology” and “transformative science.” It’s a label many companies strive to achieve, but what does it look like in practice? San Diego based genome sequencing company Illumina is a good example of a “disruptive” biotech company. They... more ►

April 21, 2015 Getting in on the ground floor Everyone has heard it said by successful people: “I got in on the ground floor.” I could kick myself for not doing so when Apple was a young company—not only in terms of investing in one company, but investing in a vision that has the potential to transform an entire market. When I was young,... more ►

April 14, 2015 High value M&As dominate Q1 2015 Guest post by Raveena Bhambra, Senior Analyst at Current Partnering The key trend of Q1 has to be the large volume of high value M&As that took place. According to Current Agreements almost 130 M&A deals were signed over the three month period between the world’s pharma and biotech... more ►

April 10, 2015 Life science dealmakers will gather in Shanghai, China next week Internationally-focused life science executives and investors will converge upon Shanghai, China next week for ChinaBio® Partnering Forum 2015. The event is China’s premier life science partnering event, and dealmakers attend with the goal of establishing cross-border partnerships to access... more ►

partnering360:Insight Latest headlines from partnering360:Insight

March 11, 2015 Sanofi , Medicen and other Paris Region clusters are leading the collaborative effort to bring ICT for Health innovation to the patient “We are working here in the Paris region to combine all the clusters that are linked to ICT for Health,” said Meunier. In particular, the three different clusters with three different technological areas of expertise involved are Medicen, Cap Digital, a software company, and Systematique Paris region, focused on ICT for Health. more ►

March 11, 2015 Targeting cancer stem cells may be key to a cure Something has been left behind in the billion-dollar "frothy" excitement over immuno-oncology therapies: recurrence of cancer and the inability to treat metastatic cancer. more ►

March 11, 2015 Academics pitch biotechs on early stage collaboration In the middle of a day filled with dealmaking and valuation of biotech assets, participants of BIO-Europe Spring® were treated to a refreshing hour of pure academia, including a half-hour lecture on the history of oncology. more ►

March 10, 2015 Gene therapies moving cautiously from bench to bedside Thanks to a series of successes reported over the past five years against a variety of genetically-triggered conditions, notably against leukemia and severe combined immunodeficiency (SCID), gene therapy has emerged from what has been called the "lost decade" and is enjoying a modest renewal of interest. more ►

March 10, 2015 Pharma gets real, in real time with patients "The FDA is a public service. They absolutely want to hear from patients and the public," said Jakob Dupont, Chief Medical Officer, OncoMed Pharmaceuticals. "If you think of the mission of regulators reviewing the packages we submit, they absolutely want to hear from patients, to see if the clinical benefit is there for approval," he told participants at BIO-Europe Spring® during the opening plenary session. more ►

Arrow Up

See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2015 EBD GmbH
Privacy Policy
Terms of Use
BIO-Europe Spring EBD Group BIO Image Map